ANDA 205484, held by Jubilant Generics. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 205484 (Solifenacin Succinate), held by Jubilant Generics, was first approved by FDA on Oct 2, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 2, 2024 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters